The greatest relative benefit was observed in the subgroup with a PD-L1 tumor proportion score of 50% or greater, a finding that was consistent with the results of previous studies of PD-1 pathway inhibition in advanced NSCLC. 14, 15, 20, 21 An important question for further study is whether the addition of pembrolizumab to pemetrexed and a platinum-based drug has greater efficacy than pembrolizumab monotherapy in these patients.